AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00454649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Description: Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m\^2) 10-minute infusion followed by cisplatin (75 mg/m\^2) infusion on Day 1 of each cycle.
Study NCT01073761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir then atazanavir/ritonavir
Description: Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days
Study NCT03600207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex training
Description: The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.
Study NCT03600207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm training
Description: The training program contains strengthening exercises on the diaphragm muscle.
Study NCT00884676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~* Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~* Schedule B: Day 1 of each 3-week cycle.
Study NCT00884676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
Study NCT04161781 — intervention group
Intervention type: DRUG
Intervention: 18F-BMS-986229 Injection
Description: Single injection prior to scan
Study NCT04161781 — intervention group
Intervention type: DRUG
Intervention: IV 18F-BMS-986229
Description: 370 MBq administered intravenously prior to scan
Study NCT04161781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT Scan
Description: Whole-body PET/CT (80 mA)
Study NCT05696379 — intervention group
Intervention type: OTHER
Intervention: Angiography derived index of micro-circulatory resistance (Angio-IMR)
Description: Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.
Study NCT02933437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ajmaline
Description: Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
Study NCT02096744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catapres-TTS-1
Description: Catapres-TTS-1 Oppanol
Study NCT01799291 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Decision Making Tutorial
Description: A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches).
Study NCT04059328 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical training
Description: This was a gyn laparoscopy training and simulation course
Study NCT03719716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticipatory care planning letter
Description: Patient letter to take to GP and GP literature
Study NCT02098889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine-N-butyl bromide(HBB)
Description: A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
Study NCT02096744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 1: Catapres-TTS-3
Description: Catapres-TTS-3 Oppanol
Study NCT02096744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 2: Catapres-TTS-3
Description: Catapres-TTS-3 Vistanex
Study NCT02096744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catapres-TTS-1
Description: Catapres-TTS-1 Vistanex
Study NCT02098889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
Study NCT01268215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infasurf
Description: Endotracheal instillation of Infasurf once per week for three weeks
Study NCT01268215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infasurf
Description: Endotracheal instillation of Infasurf once per week for three weeks
Study NCT01268215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort
Description: Endotracheal instillation, once per week for three weeks
Study NCT01268215 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: None instilled through the endotracheal tube
Study NCT02745535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir/Voxilaprevir
Study NCT01107782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: 50 mg TDS orally until birth
Study NCT01107782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50mg tid
Study NCT01237782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denture soaking solution
Description: Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
Study NCT01237782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
Study NCT02116998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 with Aluminum Hydroxide Adjuvant
Description: GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~* GB104: ABC transporter, substrate-binding protein~* GB144: Maltose/maltodextrin binding protein, ABC transporter~* GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL.
Study NCT02116998 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: normal saline, 0.5 mL per dose, IM.
Study NCT02116998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae inoculation
Description: Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
Study NCT02116998 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Streptococcus pneumoniae inoculation
Description: Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
Study NCT00459537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbinafine hydrogen chloride
Description: 10 % terbinafine hydrogen chloride (HCL)
Study NCT00459537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amorolfine nail lacquer
Description: 5 % amorolfine nail lacquer
Study NCT00896649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
Study NCT00896649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: digital mammography
Description: standard screening mammogram
Study NCT00896649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission mammography
Description: one-time positron emission mammography to compare recall rates with that of standard mammogram
Study NCT01267487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin fixed doses
Description: Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT > 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery.
Study NCT02774304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arterial line
Description: In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
Study NCT02774304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial line
Description: In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
Study NCT02774304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cheetah®
Description: In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
Study NCT02774304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cheetah®
Description: In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
Study NCT02032654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Study NCT02032654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin
Study NCT02032654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for flucloxacillin)
Description: Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
Study NCT03716752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified connective tissue graft wall with wing technique
Description: the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth
Study NCT03716752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified connective tissue graft wall with wing technique
Description: the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth
Study NCT01267487 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Heparin fixed doses
Description: Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT > 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery.
Study NCT02711046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single stage nasolabial flap
Description: The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
Study NCT03239938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modern pain neuroscience approach
Description: The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
Study NCT03239938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care evidence-based physiotherapy
Description: The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
Study NCT03346577 — intervention group
Intervention type: DEVICE
Intervention: stent or balloon
Description: Endovascular treatment with stent or balloon according to current practice
Study NCT00094432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
Study NCT00094432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Once daily, 8 weeks.
Study NCT01274910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)
Description: Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day
Study NCT01274910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsules (Placebo)
Description: Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day
Study NCT03605290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: REHAGAIT ANYLIZER
Description: Gait analysis instrumentation
Study NCT03605290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: REHAGAIT ANYLIZER
Description: Gait analysis instrumentation
Study NCT01295970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
Study NCT01295970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
Study NCT05781646 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Description: CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).
Study NCT02517671 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Enhanced External Counterpulsation (EECP)
Description: EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
Study NCT03693911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: 6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
Study NCT01303744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 1x
Description: oral tablet, 1x, once a day in the morning for 12 weeks
Study NCT01303744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 2x
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
Study NCT01303744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 3x
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
Study NCT03880344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Therapy
Description: Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
Study NCT01267487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO continuous infusion of Protamine
Description: 25mg/hour in IV continuous infusion during first 6 PO hours
Study NCT03880344 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy as post-operative rehabilitation programme for 6 months.
Study NCT03880344 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy as post-operative rehabilitation programme for 6 months.
Study NCT01267487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin and protamine titration
Description: Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve.
Study NCT01734161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8mg IV dexamethesone given
Study NCT01734161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo receive 50cc normal saline
Study NCT02420548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Ed. and Youth Skills Coaching
Description: The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
Study NCT02420548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as Usual
Description: Services as usual as provided by community service organizations from which the sample was drawn.
Study NCT02420548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Services as usual as provided by community service organizations from which the sample was drawn.
Study NCT00945009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study NCT00945009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00945009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04294914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pressor Test
Description: The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.
Study NCT04294914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test
Description: The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.
Study NCT04294914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pressor Test + Virtual Reality
Description: The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
Study NCT04294914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test + Virtual Reality
Description: The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
Study NCT01132586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01132586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01132586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT01132586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01132586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01399008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
Study NCT01399008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300 mg as active comparator
Study NCT01399008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 300 mg as active comparator
Study NCT02734407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assigned Intervention
Description: All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study as assigned intervention. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
Study NCT02734407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept 2.0 mg
Description: If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
Study NCT01860625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil patch